EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-SA 4.0

Genome-wide CRISPR/Cas9 screens reveal shared and cell-specific mechanisms of resistance to SHP2 inhibition

Wei Wei iD, Mitchell J Geer iD, Xinyi Guo iD, Igor Dolgalev iD, Neville E Sanjana iD, Benjamin G Neel iD

Journal of Experimental Medicine · 01.05.2023 · 220 (5)

DOI: 10.1084/jem.20221563 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Experimental Medicine, online erschienen am 23.02.2023. Verfasst von Wei Wei und 5 weiteren Autor:innen. Beteiligte Einrichtung: Laura and Isaac Perlmutter Cancer Center, NYU Grossman School of Medicine, NYU Langone Health , New York, NY, USA. Hauptthemen laut MEDLINE: CRISPR-Cas Systems, Signal Transduction. Die Arbeit wurde bisher 29-mal zitiert (Crossref) und nennt 75 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-SA 4.0). Gefördert von: NHGRI NIH HHS, NCI NIH HHS, National Cancer Institute.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

SHP2 (PTPN11) acts upstream of SOS1/2 to enable RAS activation. Allosteric SHP2 inhibitors (SHP2i) in the clinic prevent SHP2 activation, block proliferation of RTK- or cycling RAS mutant-driven cancers, and overcome “adaptive resistance.” To identify SHP2i resistance mechanisms, we performed genome-wide CRISPR/Cas9 knockout screens on two SHP2i-sensitive cell lines, recovering genes expected to cause resistance (NF1, PTEN, CDKN1B, LZTR1, and RASA2) and novel targets (INPPL1, MAP4K5, epigenetic modifiers). We screened 14 additional lines with a focused CRISPR library targeting common “hits” from the genome-wide screens. LZTR1 deletion conferred resistance in 12/14 lines, followed by MAP4K5 (8/14), SPRED2/STK40 (6/14), and INPPL1 (5/14). INPPL1, MAP4K5, or LZTR1 deletion reactivated ERK signaling. INPPL1-mediated sensitization to SHP2i required its NPXY motif but not lipid phosphatase activity. MAP4K5 acted upstream of MEK through a kinase-dependent target(s); LZTR1 had cell-dependent effects on RIT and RAS stability. INPPL1, MAP4K5, or LZTR1 deletion also conferred SHP2i resistance in vivo. Defining the SHP2i resistance landscape could suggest effective combination approaches.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

CRISPR-Cas SystemsSignal TransductionCell Line, TumorProtein Tyrosine Phosphatase, Non-Receptor Type 11

Substanzen

Protein Tyrosine Phosphatase, Non-Receptor Type 11

Autor:innen und Institutionen

  • Laura and Isaac Perlmutter Cancer Center, NYU Grossman School of Medicine, NYU Langone Health , New York, NY, USA.
  • Department of Biology, New York University , New York, NY, USA.
  • New York Genome Center , New York, NY, USA.

ORCID-Profile: Wei Wei, Mitchell J Geer, Xinyi Guo, Igor Dolgalev, Neville E Sanjana, Benjamin G Neel

Förderung

  • NHGRI NIH HHS
  • NCI NIH HHS
  • National Cancer Institute
  • National Human Genome Research Institute

Zitieren

APA

Wei, W., Geer, M. J., Guo, X., Dolgalev, I., Sanjana, N. E., & Neel, B. G. (2023). Genome-wide CRISPR/Cas9 screens reveal shared and cell-specific mechanisms of resistance to SHP2 inhibition. Journal of Experimental Medicine, 220(5). https://doi.org/10.1084/jem.20221563

Vancouver

Wei W, Geer MJ, Guo X, Dolgalev I, Sanjana NE, Neel BG. Genome-wide CRISPR/Cas9 screens reveal shared and cell-specific mechanisms of resistance to SHP2 inhibition. Journal of Experimental Medicine. 2023;220(5). doi:10.1084/jem.20221563

BibTeX
@article{Wei2023,
  author = {Wei, Wei and Geer, Mitchell J and Guo, Xinyi and Dolgalev, Igor and Sanjana, Neville E and Neel, Benjamin G},
  title = {Genome-wide CRISPR/Cas9 screens reveal shared and cell-specific mechanisms of resistance to SHP2 inhibition},
  journal = {Journal of Experimental Medicine},
  year = {2023},
  volume = {220},
  number = {5},
  doi = {10.1084/jem.20221563}
}
Kostenlos starten →